Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CHRISTINE THAI

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1043224587
CMS profile
1470
Location
HUNTINGTON BEACH, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$298.93

19 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $298.93 19

By paying entity

PY2021 · entire year · sorted by reported total

Page 1 of 1; records 1–19 of 19 matching records. This page contains 19 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CHRISTINE THAI

NPI 1043224587 · CMS profile ID 1470

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

HUNTINGTON BEACH, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–19 of 19 matching records. This page contains 19 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1043224587?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CHRISTINE THAI, NPI 1043224587, CMS profile ID 1470. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–19 of 19 matching records. This page contains 19 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1043224587?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). CHRISTINE THAI, NPI 1043224587, CMS profile ID 1470. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–19 of 19 matching records. This page contains 19 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1043224587?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
CHRISTINE THAI, NPI 1043224587, CMS profile ID 1470, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–19 of 19 matching records. This page contains 19 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1043224587?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

19 matching records · $298.93 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 19 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–19 of 19.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Biotech, Inc. $14.8512/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788962533 CMS
Novartis Pharmaceuticals Corporation $19.4512/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813310637 CMS
Organon LLC $13.0412/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 837178759 CMS
GlaxoSmithKline, LLC. $13.9011/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802010545 CMS
Organon LLC $5.3111/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 837178775 CMS
Janssen Biotech, Inc. $17.0811/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788962535 CMS
AbbVie Inc. $21.5710/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796147023 CMS
AstraZeneca Pharmaceuticals LP $15.9710/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829625629 CMS
E.R. Squibb & Sons, L.L.C. $23.1708/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783527893 CMS
Novartis Pharmaceuticals Corporation $15.9008/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813310633 CMS
Organon LLC $11.7308/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 837178767 CMS
Amgen Inc. $20.4306/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825221083 CMS
Janssen Biotech, Inc. $13.2106/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788962531 CMS
Janssen Biotech, Inc. $11.3605/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788962529 CMS
AbbVie Inc. $11.4304/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796147021 CMS
Amgen Inc. $19.4604/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825221091 CMS
Janssen Biotech, Inc. $12.5503/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788962537 CMS
Amgen Inc. $21.7903/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825221087 CMS
GlaxoSmithKline, LLC. $16.7301/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802522047 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,357.35 137
PY2020 $1,472.25 78
PY2021 $298.93 19
PY2022 $874.35 56
PY2023 $974.73 69
PY2024 $693.01 43
PY2025 $811.99 35

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,372,053.89 61
PY2024 Recipient $8,444.46 4
PY2024 Principal investigator $1,430,507.12 79
PY2023 Recipient $8,498.49 1
PY2023 Principal investigator $1,858,436.22 86
PY2022 Recipient $72,841.00 2
PY2022 Principal investigator $1,860,641.35 160
PY2021 Recipient $2,012.04 2
PY2021 Principal investigator $577,779.35 91
PY2020 Recipient $2,580.07 2
PY2020 Principal investigator $908,629.40 110
PY2019 Recipient $16,824.73 4
PY2019 Principal investigator $518,505.93 90

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

94 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AbbVie, Inc. $11,213.84 12/30/2019 Non-covered Recipient Entity
Care Access Research LLC
M15-998 No dispute reported 06/30/2026 647622389
Principal investigator 1 AbbVie, Inc. $1,149.20 12/30/2019 Non-covered Recipient Entity
Meridian Investigator Network LLC
M15-722 No dispute reported 06/30/2026 647622493
Principal investigator 1 AbbVie, Inc. $2,106.62 12/20/2019 Non-covered Recipient Entity
Care Access Research LLC
M15-572 No dispute reported 06/30/2026 647622367
Principal investigator 1 AbbVie, Inc. $20.32 12/12/2019 Non-covered Recipient Entity
Care Access Research LLC
M15-925 No dispute reported 06/30/2026 647622467
Principal investigator 1 AbbVie, Inc. $800.00 12/10/2019 Non-covered Recipient Entity
Meridian Investigator Network LLC
M15-722 No dispute reported 06/30/2026 647622495
Principal investigator 1 AbbVie, Inc. $750.00 12/10/2019 Non-covered Recipient Entity
Meridian Investigator Network LLC
M15-722 No dispute reported 06/30/2026 647622497
Principal investigator 1 Eli Lilly and Company $5,692.00 12/09/2019 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND ACTIVE- CONTROLLED, TREAT-THROUGH STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE No dispute reported 06/30/2026 654293157
Principal investigator 1 AbbVie, Inc. $3,416.48 12/05/2019 Non-covered Recipient Entity
Care Access Research LLC
M15-925 No dispute reported 06/30/2026 647622469
Principal investigator 1 AbbVie, Inc. $589.71 12/03/2019 Non-covered Recipient Entity
Newport Huntington Medical Group
M15-991 No dispute reported 06/30/2026 647622393
Principal investigator 1 AbbVie, Inc. $7,766.26 11/27/2019 Non-covered Recipient Entity
Care Access Research LLC
M15-554 No dispute reported 06/30/2026 647622369
Principal investigator 1 AbbVie, Inc. $12,660.60 11/27/2019 Non-covered Recipient Entity
Care Access Research LLC
M15-998 No dispute reported 06/30/2026 647622391
Principal investigator 1 AbbVie, Inc. $6,383.90 11/27/2019 Non-covered Recipient Entity
Meridian Investigator Network LLC
M15-722 No dispute reported 06/30/2026 647622499
Principal investigator 1 AbbVie, Inc. $2,285.82 11/26/2019 Non-covered Recipient Entity
Care Access Research LLC
M15-572 No dispute reported 06/30/2026 647622371
Principal investigator 1 AbbVie, Inc. $950.00 11/12/2019 Non-covered Recipient Entity
Meridian Investigator Network LLC
M15-722 No dispute reported 06/30/2026 647622501
Principal investigator 1 AbbVie, Inc. $1,750.00 11/12/2019 Non-covered Recipient Entity
Meridian Investigator Network LLC
M15-722 No dispute reported 06/30/2026 647622503
Principal investigator 1 AbbVie, Inc. $600.00 11/07/2019 Non-covered Recipient Entity
Meridian Investigator Network LLC
M15-722 No dispute reported 06/30/2026 647622505
Principal investigator 1 AbbVie, Inc. $4,235.22 11/05/2019 Non-covered Recipient Entity
Care Access Research LLC
M15-554 No dispute reported 06/30/2026 647622375
Principal investigator 1 AbbVie, Inc. $350.00 11/04/2019 Non-covered Recipient Entity
Care Access Research LLC
M15-554 No dispute reported 06/30/2026 647622373
Principal investigator 1 AbbVie, Inc. $1,892.56 11/01/2019 Non-covered Recipient Entity
Care Access Research LLC
M15-925 No dispute reported 06/30/2026 647622471
Principal investigator 1 AbbVie, Inc. $8,516.64 10/30/2019 Non-covered Recipient Entity
Care Access Research LLC
M15-998 No dispute reported 06/30/2026 647622385
Principal investigator 1 AbbVie, Inc. $6,090.00 10/17/2019 Non-covered Recipient Entity
Care Access Research LLC
M15-554 No dispute reported 06/30/2026 647622365
Principal investigator 1 AbbVie, Inc. $3,059.30 10/09/2019 Non-covered Recipient Entity
Care Access Research LLC
M15-998 No dispute reported 06/30/2026 647622387
Principal investigator 1 AbbVie, Inc. $4,912.34 10/02/2019 Non-covered Recipient Entity
Care Access Research LLC
M15-925 No dispute reported 06/30/2026 647622465
Principal investigator 1 AbbVie, Inc. $6,403.84 10/01/2019 Non-covered Recipient Entity
Care Access Research LLC
M15-554 No dispute reported 06/30/2026 647622363
Principal investigator 1 AbbVie, Inc. $5,429.68 09/27/2019 Non-covered Recipient Entity
Care Access Research LLC
M15-998 No dispute reported 06/30/2026 647622381
Principal investigator 1 AbbVie, Inc. $3,743.74 09/26/2019 Non-covered Recipient Entity
Care Access Research LLC
M15-572 No dispute reported 06/30/2026 647622357
Recipient Eli Lilly and Company $1,098.73 09/24/2019 Covered Recipient Physician A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND ACTIVE- CONTROLLED, TREAT-THROUGH STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE No dispute reported 06/30/2026 654281515
Principal investigator 1 Eli Lilly and Company $10.42 09/23/2019 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND ACTIVE- CONTROLLED, TREAT-THROUGH STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE No dispute reported 06/30/2026 654297039
Principal investigator 1 AbbVie, Inc. $6,988.54 09/12/2019 Non-covered Recipient Entity
Care Access Research LLC
M15-554 No dispute reported 06/30/2026 647622355
Principal investigator 1 AbbVie, Inc. $1,000.00 09/06/2019 Non-covered Recipient Entity
Care Access Research LLC
M15-572 No dispute reported 06/30/2026 647622359
Principal investigator 1 AbbVie, Inc. $400.00 09/06/2019 Non-covered Recipient Entity
Care Access Research LLC
M15-572 No dispute reported 06/30/2026 647622361
Principal investigator 1 AbbVie, Inc. $476.00 09/06/2019 Non-covered Recipient Entity
Care Access Research LLC
M15-998 No dispute reported 06/30/2026 647622383
Principal investigator 1 AbbVie, Inc. $250.00 09/03/2019 Non-covered Recipient Entity
Care Access Research LLC
M15-925 No dispute reported 06/30/2026 647622461
Principal investigator 1 AbbVie, Inc. $850.00 09/03/2019 Non-covered Recipient Entity
Care Access Research LLC
M15-925 No dispute reported 06/30/2026 647622463
Principal investigator 1 AbbVie, Inc. $2,623.74 08/30/2019 Non-covered Recipient Entity
Care Access Research LLC
M15-572 No dispute reported 06/30/2026 647622353
Principal investigator 1 AbbVie, Inc. $10,148.64 08/30/2019 Non-covered Recipient Entity
Care Access Research LLC
M15-998 No dispute reported 06/30/2026 647622379
Principal investigator 1 AbbVie, Inc. $8,416.60 08/30/2019 Non-covered Recipient Entity
Meridian Investigator Network LLC
M15-722 No dispute reported 06/30/2026 647622487
Principal investigator 1 AbbVie, Inc. $7,644.60 08/29/2019 Non-covered Recipient Entity
Care Access Research LLC
M15-925 No dispute reported 06/30/2026 647622457
Principal investigator 1 AbbVie, Inc. $1,200.00 08/28/2019 Non-covered Recipient Entity
Care Access Research LLC
M15-554 No dispute reported 06/30/2026 647622349
Principal investigator 1 AbbVie, Inc. $1,625.00 08/28/2019 Non-covered Recipient Entity
Care Access Research LLC
M15-554 No dispute reported 06/30/2026 647622351
Principal investigator 1 Eli Lilly and Company $50,208.00 08/26/2019 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 654290215
Principal investigator 1 AbbVie, Inc. $133.23 08/06/2019 Non-covered Recipient Entity
Meridian Investigator Network LLC
M15-722 No dispute reported 06/30/2026 647622489
Principal investigator 1 AbbVie, Inc. $422.75 08/06/2019 Non-covered Recipient Entity
Meridian Investigator Network LLC
M15-722 No dispute reported 06/30/2026 647622491
Principal investigator 1 AbbVie, Inc. $7,042.12 08/01/2019 Non-covered Recipient Entity
Care Access Research LLC
M15-925 No dispute reported 06/30/2026 647622459
Principal investigator 1 AbbVie, Inc. $750.00 07/30/2019 Non-covered Recipient Entity
Care Access Research LLC
M15-554 No dispute reported 06/30/2026 647622449
Principal investigator 1 AbbVie, Inc. $4,253.18 07/30/2019 Non-covered Recipient Entity
Care Access Research LLC
M15-572 No dispute reported 06/30/2026 647622451
Principal investigator 1 AbbVie, Inc. $2,872.50 07/30/2019 Non-covered Recipient Entity
Meridian Investigator Network LLC
M15-722 No dispute reported 06/30/2026 647622485
Principal investigator 1 AbbVie, Inc. $309.12 07/26/2019 Non-covered Recipient Entity
Care Access Research LLC
M15-572 No dispute reported 06/30/2026 647622453
Principal investigator 1 AbbVie, Inc. $5,328.00 07/22/2019 Non-covered Recipient Entity
Meridian Investigator Network LLC
M15-722 No dispute reported 06/30/2026 647622483
Principal investigator 1 AbbVie, Inc. $85.25 07/18/2019 Non-covered Recipient Entity
Care Access Research LLC
M15-925 No dispute reported 06/30/2026 647622455
Principal investigator 1 AbbVie, Inc. $325.12 06/27/2019 Non-covered Recipient Entity
Care Access Research LLC
M15-572 No dispute reported 06/30/2026 647622447
Principal investigator 1 AbbVie, Inc. $7,475.68 06/27/2019 Non-covered Recipient Entity
Meridian Investigator Network LLC
M15-722 No dispute reported 06/30/2026 647622475
Principal investigator 1 AbbVie, Inc. $1,154.25 06/24/2019 Non-covered Recipient Entity
Meridian Investigator Network LLC
M15-722 No dispute reported 06/30/2026 647622477
Principal investigator 1 AbbVie, Inc. $683.00 06/24/2019 Non-covered Recipient Entity
Meridian Investigator Network LLC
M15-722 No dispute reported 06/30/2026 647622479
Principal investigator 1 AbbVie, Inc. $5,328.00 06/24/2019 Non-covered Recipient Entity
Meridian Investigator Network LLC
M15-722 No dispute reported 06/30/2026 647622481
Principal investigator 1 AbbVie, Inc. $6,090.00 06/21/2019 Non-covered Recipient Entity
Care Access Research LLC
M15-572 No dispute reported 06/30/2026 647622445
Principal investigator 1 AbbVie, Inc. $14,489.84 06/14/2019 Non-covered Recipient Entity
Care Access Research LLC
M15-925 No dispute reported 06/30/2026 647622443
Principal investigator 1 Eli Lilly and Company $745.50 06/10/2019 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 654292015
Principal investigator 1 Eli Lilly and Company $1,518.28 06/07/2019 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 654292271
Principal investigator 1 AbbVie, Inc. $8,349.00 06/03/2019 Non-covered Recipient Entity
Care Access Research LLC
M15-998 No dispute reported 06/30/2026 647622377
Principal investigator 1 AbbVie, Inc. $14,541.30 05/31/2019 Non-covered Recipient Entity
Care Access Research LLC
M15-554 No dispute reported 06/30/2026 647622431
Principal investigator 1 AbbVie, Inc. $6,684.44 05/29/2019 Non-covered Recipient Entity
Care Access Research LLC
M15-572 No dispute reported 06/30/2026 647622435
Principal investigator 1 AbbVie, Inc. $171.70 05/10/2019 Non-covered Recipient Entity
Care Access Research LLC
M15-572 No dispute reported 06/30/2026 647622437
Principal investigator 1 AbbVie, Inc. $432.25 05/10/2019 Non-covered Recipient Entity
Care Access Research LLC
M15-572 No dispute reported 06/30/2026 647622439
Principal investigator 1 AbbVie, Inc. $12,000.00 05/10/2019 Non-covered Recipient Entity
Meridian Investigator Network LLC
M15-722 No dispute reported 06/30/2026 647622473
Principal investigator 1 AbbVie, Inc. $8,591.20 05/09/2019 Non-covered Recipient Entity
Care Access Research LLC
M15-925 No dispute reported 06/30/2026 647622441
Principal investigator 1 AbbVie, Inc. $1,531.90 05/03/2019 Non-covered Recipient Entity
Care Access Research LLC
M15-554 No dispute reported 06/30/2026 647622433
Principal investigator 1 AbbVie, Inc. $1,956.86 04/29/2019 Non-covered Recipient Entity
Care Access Research LLC
M15-572 No dispute reported 06/30/2026 647622427
Principal investigator 1 Eli Lilly and Company $118.50 04/25/2019 Non-covered Recipient Entity
VANDERBILT UNIVERSITY MEDICAL CENTER
A 52 WEEK MULTICENTER RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF IXEKIZUMAB LY2439821 IN BDMARD NAIVE PATIENTS WITH NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS No dispute reported 06/30/2026 654299075
Principal investigator 1 AbbVie, Inc. $8,626.12 04/04/2019 Non-covered Recipient Entity
Care Access Research LLC
M15-925 No dispute reported 06/30/2026 647622429
Principal investigator 1 AbbVie, Inc. $10,411.72 03/29/2019 Non-covered Recipient Entity
Care Access Research LLC
M15-572 No dispute reported 06/30/2026 647622405
Principal investigator 1 AbbVie, Inc. $12,156.66 03/28/2019 Non-covered Recipient Entity
Care Access Research LLC
M15-554 No dispute reported 06/30/2026 647622401
Principal investigator 1 Eli Lilly and Company $10,055.00 03/26/2019 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A 52 WEEK MULTICENTER RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF IXEKIZUMAB LY2439821 IN BDMARD NAIVE PATIENTS WITH NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS No dispute reported 06/30/2026 654289281
Principal investigator 1 AbbVie, Inc. $13,750.00 03/20/2019 Non-covered Recipient Entity
Care Access Research LLC
M15-925 No dispute reported 06/30/2026 647622399
Principal investigator 1 AbbVie, Inc. $250.00 03/20/2019 Non-covered Recipient Entity
Care Access Research LLC
M15-554 No dispute reported 06/30/2026 647622403
Principal investigator 1 AbbVie, Inc. $13,750.00 03/12/2019 Non-covered Recipient Entity
Care Access Research LLC
M15-572 No dispute reported 06/30/2026 647622407
Principal investigator 1 Eli Lilly and Company $34,949.00 03/12/2019 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A MULTICENTER LONG-TERM EXTENSION STUDY OF 104 WEEKS INCLUDING A DOUBLE BLIND PLACEBO CONTROLLED 40 WEEK RANDOMIZED WITHDRAWAL RETREATMENT PERIOD TO EVALUATE THE MAINTENANCE OF TREATMENT EFFECT OF IXEKIZUMAB LY2439821 IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS No dispute reported 06/30/2026 654289013
Principal investigator 1 Eli Lilly and Company $3,869.67 03/12/2019 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A MULTICENTER RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED 16 WEEK STUDY FOLLOWED BY LONG TERM EVALUATION OF EFFICACY AND SAFETY OF IXEKIZUMAB LY2439821 IN TNFI EXPERIENCED PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS No dispute reported 06/30/2026 654289501
Principal investigator 1 AbbVie, Inc. $45.11 03/05/2019 Non-covered Recipient Entity
Care Access Research LLC
M15-925 No dispute reported 06/30/2026 647622409
Principal investigator 1 AbbVie, Inc. $1,243.53 03/01/2019 Non-covered Recipient Entity
Care Access Research LLC
M15-554 No dispute reported 06/30/2026 647622411
Principal investigator 1 AbbVie, Inc. $12,600.76 03/01/2019 Non-covered Recipient Entity
Care Access Research LLC
M15-925 No dispute reported 06/30/2026 647622413
Principal investigator 1 AbbVie, Inc. $4,065.52 03/01/2019 Non-covered Recipient Entity
Care Access Research LLC
M15-554 No dispute reported 06/30/2026 647622415
Principal investigator 1 AbbVie, Inc. $7,833.34 02/28/2019 Non-covered Recipient Entity
Care Access Research LLC
M15-572 No dispute reported 06/30/2026 647622395
Principal investigator 1 AbbVie, Inc. $18,414.32 02/04/2019 Non-covered Recipient Entity
Care Access Research LLC
M15-554 No dispute reported 06/30/2026 647622397
Principal investigator 1 AbbVie, Inc. $24,644.52 01/31/2019 Non-covered Recipient Entity
Care Access Research LLC
M15-925 No dispute reported 06/30/2026 647622417
Principal investigator 1 AbbVie, Inc. $1,747.20 01/29/2019 Non-covered Recipient Entity
Care Access Research LLC
M15-572 No dispute reported 06/30/2026 647622419
Principal investigator 1 Eli Lilly and Company $139.78 01/28/2019 Non-covered Recipient Entity
SLOAN KETTERING INST FOR CANCER RESEARCH
A MULTICENTER RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED 16 WEEK STUDY FOLLOWED BY LONG TERM EVALUATION OF EFFICACY AND SAFETY OF IXEKIZUMAB LY2439821 IN TNFI EXPERIENCED PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS No dispute reported 06/30/2026 654292561
Principal investigator 1 Eli Lilly and Company $1,018.20 01/28/2019 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A MULTICENTER LONG-TERM EXTENSION STUDY OF 104 WEEKS INCLUDING A DOUBLE BLIND PLACEBO CONTROLLED 40 WEEK RANDOMIZED WITHDRAWAL RETREATMENT PERIOD TO EVALUATE THE MAINTENANCE OF TREATMENT EFFECT OF IXEKIZUMAB LY2439821 IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS No dispute reported 06/30/2026 654297677
Recipient Eli Lilly and Company $4,183.00 01/22/2019 Covered Recipient Physician A MULTICENTER LONG-TERM EXTENSION STUDY OF 104 WEEKS INCLUDING A DOUBLE BLIND PLACEBO CONTROLLED 40 WEEK RANDOMIZED WITHDRAWAL RETREATMENT PERIOD TO EVALUATE THE MAINTENANCE OF TREATMENT EFFECT OF IXEKIZUMAB LY2439821 IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS No dispute reported 06/30/2026 654281183
Recipient Eli Lilly and Company $5,609.00 01/15/2019 Covered Recipient Physician A 52 WEEK MULTICENTER RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF IXEKIZUMAB LY2439821 IN BDMARD NAIVE PATIENTS WITH NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS No dispute reported 06/30/2026 654281709
Principal investigator 1 AbbVie, Inc. $1,092.00 01/09/2019 Non-covered Recipient Entity
Care Access Research LLC
M15-925 No dispute reported 06/30/2026 647622421
Recipient Eli Lilly and Company $5,934.00 01/08/2019 Covered Recipient Physician A MULTICENTER RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED 16 WEEK STUDY FOLLOWED BY LONG TERM EVALUATION OF EFFICACY AND SAFETY OF IXEKIZUMAB LY2439821 IN TNFI EXPERIENCED PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS No dispute reported 06/30/2026 654281961
Principal investigator 1 AbbVie, Inc. $14,446.62 01/04/2019 Non-covered Recipient Entity
Care Access Research LLC
M15-925 No dispute reported 06/30/2026 647622423
Principal investigator 1 AbbVie, Inc. $15,404.28 01/04/2019 Non-covered Recipient Entity
Care Access Research LLC
M15-554 No dispute reported 06/30/2026 647622425